Industry warns that Biden’s drug price negotiations may lead to shortages of vital drugs.
Pharmaceutical Industry Experts Warn of Growing Medication Shortages
Pharmaceutical industry experts are raising concerns about the potential impact of the Medicare Drug Price Negotiation Program on the availability of common small molecule medications. These experts argue that the program, created by the Inflation Reduction Act, could lead to shortages of medications like aspirin and antibiotics.
Last week, the Centers for Medicare & Medicaid Services (CMS) announced the 10 medications that will be subject to maximum fair price negotiation with pharmaceutical companies for Part D Medicare coverage. This negotiation process, set to take effect in 2026, is part of President Joe Biden’s domestic legislation bill.
Impact on Medication Prices and Investment
Under the new legislation, the secretary of health and human services will have the authority to negotiate prices for medications that pose the greatest cost to the Medicare program. Noncompliance with the negotiated prices could result in penalties of up to 95% of profits for drug manufacturers.
While the Biden administration claims that these negotiations will lead to savings for Medicare, experts caution that price controls may discourage investment in pharmaceuticals due to limited profits. A study conducted by the University of Chicago estimates that price controls could reduce research and development investment by $663 billion through 2039, potentially resulting in the loss of up to 135 new drugs.
However, industry experts argue that the impact of reduced investment will primarily affect small molecule medications. Small molecule drugs, such as aspirin, allergy medications, and antibiotics, are typically administered by patients at home and have a smaller chemical makeup. In contrast, biologics, which are derived from living cells, are more complex to manufacture and often require administration at healthcare facilities.
Concerns about Incentives and Supply
The Inflation Reduction Act allows the CMS to impose price controls on biologic drugs after 13 years on the market, while small molecules only have nine years before becoming eligible for negotiation. This discrepancy may discourage investment in small molecule medications and shift resources towards biologics.
Experts argue that this emphasis on biologics could negatively impact market resiliency during emergencies, such as natural disasters or pandemics. With fewer manufacturing facilities capable of producing large quantities of small molecule medications, the supply may be insufficient to meet the demand.
Disincentivizing Small Molecule Innovation
According to industry representatives, the Inflation Reduction Act’s differential treatment of biologics and small molecules reflects a misunderstanding of the market. They argue that while biologics may hold promise for curative therapies, innovation in treatments has focused on making existing medications more accessible through pill forms.
Despite concerns raised by experts, the CMS maintains that there is no evidence linking the price exclusivity differential to medication shortages. President Biden has accused “MAGA Republicans” of seeking to eliminate the drug price negotiation program, but industry representatives emphasize the need for both small molecules and biologics to have 13 years of price exclusivity.
It remains to be seen how the Medicare Drug Price Negotiation Program will impact medication availability and innovation in the pharmaceutical industry.
Click here to read more from the Washington Examiner.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
